Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases (CiPHER)

Trial Profile

Phase II multicentre study assessing the efficacy of Cabazitaxel in Patients with HER2-negative metastatic breast cancer and having unresectable brain metastases (CiPHER)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Apr 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cabazitaxel (Primary)
  • Indications Advanced breast cancer; Brain metastases
  • Focus Therapeutic Use
  • Acronyms CiPHER
  • Most Recent Events

    • 17 Dec 2015 Accrual to date is 2% according to United Kingdom Clinical Research Network.
    • 24 Oct 2015 Accrual to date is 1% according to United Kingdom Clinical Research Network.
    • 08 Feb 2015 Accrual to date is 0% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top